Frontiers in Endocrinology

Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients

By Laura A. Lee, Abby F. Tang, Anna E. Asako, Fumihiko Urano

Cohort study of 84 peopleInterventions

The paper

Laura A. Lee, Abby F. Tang, Anna E. Asako, Fumihiko Urano

Washington University in St. Louis

Frontiers in Endocrinology, 30 Jul 2026

doi.org/10.3389/fendo.2026.1847818 PubMed 42597412

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Neurology Genetics4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk